MONOPAR THERAPEUTICS INC

MNPRNASDAQ

🏆 #2449 by market capEarnings Nov 11US Equity

$111.46▼ $2.92 (−2.62%)

Live

1h▲ 0.0%

24h▼ 2.6%

7d▼ 6.8%

14d▲ 3.4%

30d▲ 8.6%

1y▲ 254.9%

🏦Market Cap

$747M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $110.86 – $112.60
52-Week Range: $29.18 – $124.82
Volume: $2.11B
Avg Volume: $2.23B
Shares Outstanding: 6.7M
Next Earnings: Sep 18, 2026

Fundamentals Snapshot

Annual Revenue: $89M
Last Q Revenue: $24M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.90
Dividend Yield: —

Why Investors Own MNPR

✓High-growth profile — revenue up +59.2% YoY with expanding US Equity exposure.
✓Healthy economics — 28% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$89M▲ +58.6% YoY

Gross Margin (TTM)

27.8%▲ +0.5% YoY

Operating Income (TTM)

$11M▲ +58.6% YoY

Free Cash Flow (TTM)

$18M▲ +58.6% YoY

About MONOPAR THERAPEUTICS INC

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

🦦